NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug shows promise against leading cause of vision loss in seniors
Disease control CompletedThis study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. About 488 adults aged 50-85 with active disease received injections into the eye over a year. The goal w…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New eye drug OLN324 shows promise in early trial for two blinding diseases
Disease control CompletedThis early-phase study tested a new eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves through the body, while also looking for early signs it m…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated May 04, 2026 16:17 UTC